Traditional diagnostic methods for hantavirus often struggle to provide actionable data in acute care settings, as specific PCR or serology tests may be unavailable or slow to return results. TriVerity®, developed by the Sunnyvale-based firm Inflammatix, pivots away from pathogen detection to analyze the patient's immune response. By measuring 29 specific mRNA signatures from a single blood sample, the test provides a risk profile for bacterial or viral infection and predicts the likelihood of ICU-level care within a week.

Dr. Jana Broadhurst, medical director at the U.S. Region 7 Emerging Special Pathogens Treatment Center, notes that early-stage hantavirus symptoms are frequently indistinguishable from routine illnesses. The collaboration aims to standardize triage and isolation protocols by providing objective data on a patient's immune trajectory. Inflammatix CEO Tim Sweeney emphasized that the technology is designed to replace clinical guesswork with real-time immune system insights, a capability supported by federal funding from BARDA. The system delivers results in approximately 30 minutes, allowing emergency departments to make immediate decisions regarding antimicrobial therapy and patient disposition.